Pegfilgrastim supports delivery of CHO-R chemotherapy administered every 14 days: A randomized phase II study

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 46-47

  Lopez, Andres ^a   de Sevilla, Alberto Fernandez ^a   Castaigne, Sylvie ^a   Greil, Richard ^a   Sierra, Jorge ^a   Sanchez, Jordi ^a   Easton, Valerie ^a   Bacon, Pamela ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HUMAN; LEUKOCYTE COUNT; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPEN STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

EID: 15944381536     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Lopez A, Fernandez de Sevilla A, Castaigne S, et al. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomised phase II study. Poster presented at the 46th Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diego, Calif. Abstract 3311.